Evaluation of the Protective Effects of Cordyceps Cicadae on Visual Function and Anti-Fatigue Performance in Esports Athletes

NCT07135193 | Active Not Recruiting

• 1 other identifier: CS1-25024
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study is to evaluate, through a clinical human consumption trial, the effects of taking two capsules (each containing 250 mg of Cordyceps cicadae mycelium, for a total intake of 500 mg per dose) of Grape King Cordyceps cicadae mycelium on visual function and anti-fatigue performance in esports athletes.

Conditions

Visual Acuity; Accommodation; Dry Eye

Outcome Measures

Primary Outcomes (7)

• Tear break-up time

  Tear film break-up time (TBUT) on the corneal surface will be recorded in seconds using corneal topography.

  3 hours

• Eye fatigue questionnaire

  The Ocular Surface Disease Index (OSDI) was used to assess visual fatigue. The subjects were asked to fill in the questionnaire before and after taking the medicine, and the scores were calculated. Symptoms include eyestrain, discomfort, burning, irritation, pain, soreness, eye pain, double vision, photophobia, blurriness, itching, tearing, dryness, and foreign body sensation

  3 hours

• Accommodative Facility

  Use +/- 0.50D flip mirror and special optometry cards to test the number of optometry cards that the patient can read within one minute and record the number of flip cycles.

  3 hours

• Visual acuity measurement

  Examinations include (a) distance visual acuity (DVA) and (b) near visual acuity (NVA), recorded using the Snellen chart.

  3 hours

• Intraocular Pressure

  The intraocular pressure (IOP) of the subjects was measured by non-contact intraocular pressure measurement in mmHg.

  3 hours

• Tear meniscus height (TMH)

  Tear meniscus height (TMH) will be evaluated using slit-lamp biomicroscopy and recorded in millimeters.

  3 hours

• Meibomian gland observation

  The meibomian glands will be evaluated using corneal topography to document their morphology, quantity, and size.

  3 hours

Study Arms (2)

Experimental Arm

EXPERIMENTAL

Cordyceps cicadae 500mg

Dietary Supplement: Cordyceps cicadae

Placebo Comparator Arm

PLACEBO COMPARATOR

Placebo

Dietary Supplement: Blank control

Interventions

Cordyceps cicadae DIETARY_SUPPLEMENT

Cordyceps cicadae 500mg

Experimental Arm

Blank control DIETARY_SUPPLEMENT

Blank control

Placebo Comparator Arm

Eligibility Criteria

• Age: 30 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• People with myopia less than 700 degrees
• Willing to participate in this study and sign the consent form

You may not qualify if:

• (1) Those who have recently consumed related eye care products
• (2) Those who have had eye infections or surgery in the past three months
• (3) Those who have been diagnosed with eye diseases by an ophthalmologist (such as glaucoma, cataracts, macular degeneration, diabetic retinopathy, etc., or have undergone eye surgery such as cataract surgery, retinal laser surgery, myopia laser surgery, etc., which will be excluded before accepting the case)
• (4) Those who are allergic to cicada fungus

Sponsors & Collaborators

• China Medical University Hospital: lead

Study Sites (1)

Chung Shan Medical University Hui-Wen Lin lab

Taichung, Taiwan

Location

MeSH Terms

Conditions

Dry Eye Syndromes

Condition Hierarchy (Ancestors)

Lacrimal Apparatus Diseases; Eye Diseases

Study Officials

• Hui-Wen Lin, Ph.D

  Chung Shang medical university

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Ph.D

Study Record Dates

• First Submitted: August 11, 2025
• First Posted: August 21, 2025
• Study Start: August 12, 2025
• Primary Completion: August 13, 2025
• Study Completion: December 31, 2025
• Last Updated: August 21, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

TW (1)